Team:UCL/Background

From 2013.igem.org

(Difference between revisions)
 
(63 intermediate revisions not shown)
Line 6: Line 6:
<script type="text/javascript" src="https://2013.igem.org/Team:UCL/static/head.js?action=raw&ctype=text/javascript">  
<script type="text/javascript" src="https://2013.igem.org/Team:UCL/static/head.js?action=raw&ctype=text/javascript">  
</script>
</script>
 +
 +
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:UCL/static/subheadingstyles.css?action=raw&ctype=text/css" />
<script>
<script>
-
var word1 = "BACKGROUND";
+
var word1 = "BACK";
-
var word2 = ",;";
+
var word2 = "GROUND";
</script>
</script>
Line 37: Line 39:
<div id="container">
<div id="container">
-
<!-- START CONTENT ---------------------------------------------------------------------------------------------------->
+
<!-- START CONTENT-------------------------------------------------------------------------------------------------->
<div class="gap">
<div class="gap">
</div>
</div>
Line 45: Line 47:
<div class="col_left">
<div class="col_left">
-
                <p class="major_title">RESEARCH</p>
+
<p class="major_title">RELATED NEUROSCIENCE</p>
-
+
-
<p class="minor_title">Alzheimer's Disease</p>
+
-
+
-
<p class="body_text">
+
-
Dementia is an age related neurodegenerative condition, characterised by failure of recent memory and intellectual functions (attention, language, visual-spatial orientation, abstract thinking, judgement), and tends to progress steadily. These changes are due to the mounting dysfunction and death of brain cells, called neurons, that are responsible for the storage and computation of information. Late stages of the disease often see patients bedridden, mute and incontinent. Although some drugs can temporarily improve memory, pharmaceutical research, through enlightening, has been clinically unsuccessful.  At present there are no treatments that can halt, let alone revert, the inexorable progression of dementia. </p>
+
-
<p class="body_text">
+
-
Alzheimer’s disease is the most common of the dementias, afflicting 5-10% of the US population over 45, and 2% of the population in industrialised countries (Mattson 2004). It is
+
-
predicted that its incidence will rocket up threefold 50 years from now (http://www.alz.org).
+
-
It is mainly ‘late-onset’, arising after the age of 60, though rarer early onset types exist. Because there are other forms of dementia and other means of memory impairment, AD can only be verified post-mortem by examining the deceased’s brain. </p>
+
-
</div>
+
-
            <div class="col_right" style="background-image:url('https://static.igem.org/mediawiki/2013/7/7f/Homepage_poster.png');">
+
<p class="minor_title">Neuro-genetic engineering</p>
 +
 
 +
<p class="abstract_text" style="color:#404040;">
 +
Our project this year blends the fields of synthetic biology and neuroscience. We aim to demonstrate that genetic engineering techniques can be applied to the central nervous system, in order to rectify abnormalities in, for example, the brain on a cellular and/or macromolecular level. Such a novel application of synthetic biology could offer new ways to treat certain brain diseases, such as Alzheimer’s disease, for which modern pharmaceutical treatment is purely symptomatic.<br><br>
 +
</p>
 +
<p class="abstract_text" style="color:#C14645;">
 +
Click the abstracts below to read more.
 +
</p>
</div>
</div>
 +
 +
            <div class="col_right">
 +
<a href="https://static.igem.org/mediawiki/2013/7/7f/Homepage_poster.png" data-lightbox="image-1" title="caption">
 +
<img src="https://static.igem.org/mediawiki/2013/7/7f/Homepage_poster.png">
 +
</a>
 +
</div>
</div>
</div>
Line 68: Line 73:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration">
+
<div class="col_illustration" style="background-image:url('https://static.igem.org/mediawiki/2013/3/3a/Holding_hands.jpg');">
</div>
</div>
<div class="col_abstract">
<div class="col_abstract">
 +
<a href="https://2013.igem.org/Team:UCL/Background/Alzheimers">
 +
<p class="abstract_title">Alzheimer's Disease</p>
 +
<p class="abstract_text">
 +
Alzheimer’s disease is the most prevalent form of dementia. Symptoms include memory loss, mood fluctuations and problems with communication and reasoning. It is a physical, degenerative condition that causes cell death in the brain.
 +
</p>
 +
</a>
</div>
</div>
-
<div class="col_links">
+
 +
</div>
 +
 +
<div class="gap">
 +
</div>
 +
 +
<div class="row_small">
 +
 +
<div class="col_illustration" style="background-image:url('https://static.igem.org/mediawiki/2013/e/e4/Amyloid_plaques_alzheimer_disease_HE_stain.jpg');">
</div>
</div>
 +
 +
<div class="col_abstract">
 +
<a href="https://2013.igem.org/Team:UCL/Background/Neuropathology">
 +
<p class="abstract_title">Neuropathology</p>
 +
<p class="abstract_text">There are many hypotheses on the causes for Alzheimer’s disease, though there are three accepted signs in the brain: plaques, tangles and cell death. We focus on the so called ‘Amyloid Hypothesis’.
 +
</p>
 +
</a>
 +
</div>
 +
</div>
</div>
Line 81: Line 109:
<div class="gap">
<div class="gap">
</div>
</div>
-
<!-- END CONTENT ------------------------------------------------------------------------------------------------------>
+
 +
<div class="row_small">
 +
 +
<div class="col_illustration" style="background-image:url('https://static.igem.org/mediawiki/2013/0/0b/Microglia_and_neurons.jpg');">
 +
</div>
 +
 +
<div class="col_abstract">
 +
 
 +
 
 +
<a href="https://2013.igem.org/Team:UCL/Background/Microglia">
 +
<p class="abstract_title">Microglia</p>
 +
<p class="abstract_text">Microglia are the resident, mobile immune cells in the brain, performing many of the same roles as one’s white blood cells. In our project, we try to use microglia as a chassis for our genetic circuit.
 +
</p>
 +
</a>
 +
</div>
 +
 +
 +
</div>
 +
 +
<div class="gap">
 +
</div>
 +
 
 +
 
 +
<!-- END CONTENT ---------------------------------------------------------------------------------------------------->
</div>
</div>

Latest revision as of 17:33, 19 September 2013

RELATED NEUROSCIENCE

Neuro-genetic engineering

Our project this year blends the fields of synthetic biology and neuroscience. We aim to demonstrate that genetic engineering techniques can be applied to the central nervous system, in order to rectify abnormalities in, for example, the brain on a cellular and/or macromolecular level. Such a novel application of synthetic biology could offer new ways to treat certain brain diseases, such as Alzheimer’s disease, for which modern pharmaceutical treatment is purely symptomatic.

Click the abstracts below to read more.

Alzheimer's Disease

Alzheimer’s disease is the most prevalent form of dementia. Symptoms include memory loss, mood fluctuations and problems with communication and reasoning. It is a physical, degenerative condition that causes cell death in the brain.

Neuropathology

There are many hypotheses on the causes for Alzheimer’s disease, though there are three accepted signs in the brain: plaques, tangles and cell death. We focus on the so called ‘Amyloid Hypothesis’.

Microglia

Microglia are the resident, mobile immune cells in the brain, performing many of the same roles as one’s white blood cells. In our project, we try to use microglia as a chassis for our genetic circuit.

Retrieved from "http://2013.igem.org/Team:UCL/Background"